ZA200308589B - Recombinant fusion proteins and the trimers thereof. - Google Patents

Recombinant fusion proteins and the trimers thereof.

Info

Publication number
ZA200308589B
ZA200308589B ZA200308589A ZA200308589A ZA200308589B ZA 200308589 B ZA200308589 B ZA 200308589B ZA 200308589 A ZA200308589 A ZA 200308589A ZA 200308589 A ZA200308589 A ZA 200308589A ZA 200308589 B ZA200308589 B ZA 200308589B
Authority
ZA
South Africa
Prior art keywords
trimers
fusion proteins
recombinant fusion
recombinant
proteins
Prior art date
Application number
ZA200308589A
Other languages
English (en)
Inventor
Jurg Tschopp
Pascal Schneider
Original Assignee
Apoxis Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apoxis Sa filed Critical Apoxis Sa
Publication of ZA200308589B publication Critical patent/ZA200308589B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA200308589A 2001-05-08 2003-11-04 Recombinant fusion proteins and the trimers thereof. ZA200308589B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10122140A DE10122140A1 (de) 2001-05-08 2001-05-08 Rekombinante Fusionsproteine und deren Trimere

Publications (1)

Publication Number Publication Date
ZA200308589B true ZA200308589B (en) 2004-07-12

Family

ID=7683900

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200308589A ZA200308589B (en) 2001-05-08 2003-11-04 Recombinant fusion proteins and the trimers thereof.

Country Status (12)

Country Link
US (1) US20040197876A1 (fr)
EP (1) EP1385966A2 (fr)
JP (1) JP2004534529A (fr)
CN (1) CN1602358A (fr)
BR (1) BR0209471A (fr)
CA (1) CA2452245A1 (fr)
DE (1) DE10122140A1 (fr)
IL (1) IL158751A0 (fr)
MX (1) MXPA03010263A (fr)
PL (1) PL367031A1 (fr)
WO (1) WO2002090553A2 (fr)
ZA (1) ZA200308589B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10247755B4 (de) * 2002-10-14 2006-01-19 Pfizenmaier, Klaus, Prof. Dr. Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
CA2515100A1 (fr) * 2003-02-06 2004-08-19 Micromet Ag Reponse de lymphocyte t durable
DE602004022390D1 (de) 2003-03-26 2009-09-17 Apogenix Gmbh Verbesserte fc-fusionsproteine
US20050143297A1 (en) * 2003-05-26 2005-06-30 Jean-Pierre Rosat Method for the administration of ligands, agonists of ligands of the TNF family with reduced toxicity
US7268116B2 (en) * 2003-10-02 2007-09-11 Genhunter Corp. Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins
CN101384614A (zh) * 2005-08-15 2009-03-11 加利福尼亚大学董事会 Vegf活化的fas配体
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
AU2013203061B2 (en) * 2007-07-10 2016-07-28 Apogenix Ag TNF superfamily collectin fusion proteins
EP3072903B1 (fr) * 2007-07-10 2017-10-25 Apogenix AG Protéines de fusion collectines de la superfamille des tnf
EP2540740B1 (fr) * 2008-06-17 2014-09-10 Apogenix GmbH Récepteurs multimériques TNF
EP2313108A4 (fr) * 2008-06-30 2013-06-12 Us Army As Represented By The Secretary Of The Army Vaccin antipaludéen de nanoparticules de polypeptide auto-assemblées
PT2310509E (pt) * 2008-07-21 2015-05-19 Apogenix Gmbh Moléculas de tnfsf em cadeia simples
JP5844158B2 (ja) 2009-01-09 2016-01-13 アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ 三量体形成融合タンパク質
GB0920127D0 (en) * 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
TWI476001B (zh) * 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Ｆｃ融合蛋白及其用途
JP6050671B2 (ja) * 2012-12-07 2016-12-21 ダイキン工業株式会社 空気調和装置の配管ユニットの製造方法および空気調和装置の施工方法
WO2014100913A1 (fr) * 2012-12-24 2014-07-03 Beijing Anxinhuaide Biotech. Co., Ltd Amélioration de la demi-vie d'un polypeptide thérapeutique par fusion avec une protéine d'échafaudage trimère via un espaceur
JP2014124186A (ja) * 2012-12-26 2014-07-07 Industrial Technology Research Institute 多価抗体フラグメントおよびその三量体化複合体
US10533054B2 (en) 2013-01-31 2020-01-14 Thomas Jefferson University Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system
WO2015052716A1 (fr) * 2013-10-09 2015-04-16 Cellect Biotechnology Ltd. Activation de progéniteurs hématopoiétiques par exposition avant la greffe aux ligands de mort
CN103739714B (zh) * 2013-12-30 2016-06-01 江苏众红生物工程创药研究院有限公司 TNFα与DC-SIGN的融合蛋白及其应用
JP2014218510A (ja) * 2014-08-11 2014-11-20 アポゲニクスゲゼルシャフト ミット ベシュレンクテルハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ 三量体形成融合タンパク質
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
EP3365363A1 (fr) * 2015-10-23 2018-08-29 Apogenix AG Protéines agonistes du récepteur gitr à chaîne unique
JP2016210791A (ja) * 2016-08-03 2016-12-15 アポゲニクス アーゲー 三量体形成融合タンパク質
US11377490B2 (en) 2017-05-31 2022-07-05 Sichuan Clover Biopharmaceuticals, Inc Method for treating cancer using disulfide-linked trimeric 4-1BBL
US20210371825A1 (en) * 2018-10-16 2021-12-02 Board Of Regents, The University Of Texas System Compositions for and methods of producing tumor organoids
WO2021249116A1 (fr) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Compositions de vaccin contre le coronavirus, procédés et utilisations associées
WO2021249010A1 (fr) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Compositions, procédés et utilisations de diagnostic de coronavirus
WO2021249013A1 (fr) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Compositions de vaccin, procédés et utilisations associées

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8412517D0 (en) * 1984-05-16 1984-06-20 Nagai K Recombinant fusion proteins
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
JP2000125872A (ja) * 1998-09-07 2000-05-09 Terumo Corp 三量体キメラタンパク質およびキメラタンパク質を含有するコラーゲンマトリックス
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
WO2002079415A2 (fr) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reduction de l'immunogenicite de proteines de fusion

Also Published As

Publication number Publication date
WO2002090553A2 (fr) 2002-11-14
PL367031A1 (en) 2005-02-21
IL158751A0 (en) 2004-05-12
JP2004534529A (ja) 2004-11-18
CN1602358A (zh) 2005-03-30
BR0209471A (pt) 2004-07-06
DE10122140A1 (de) 2002-11-28
WO2002090553A3 (fr) 2003-05-01
CA2452245A1 (fr) 2002-11-14
MXPA03010263A (es) 2005-03-07
US20040197876A1 (en) 2004-10-07
EP1385966A2 (fr) 2004-02-04

Similar Documents

Publication Publication Date Title
ZA200308589B (en) Recombinant fusion proteins and the trimers thereof.
AU2002364586A8 (en) Albumin fusion proteins
AU2002364587A8 (en) Albumin fusion proteins
PL362324A1 (en) Artificial fusion proteins with reduced immunogenicity
EP1451293A4 (fr) Nouvelles proteines de fusion sulfurylase-luciferase et sulfurylase thermostable
AU2003239365A8 (en) Recombinant glycosyltransferase fusion proteins
EP1278544A4 (fr) Proteines hybrides d'albumine
IL160127A0 (en) Tacis and br3 polypeptides and uses thereof
AU2002332041A1 (en) Albumin fusion proteins
GB9913437D0 (en) Fusion proteins
AUPR546801A0 (en) Recombinant antibodies
EP1433849A4 (fr) Nouveau polypeptide, adn associe et utilisation de ce polypeptide
AU2002341202A1 (en) Recombinant fusion proteins and the trimers thereof
IL145233A0 (en) Recombinant plant proteins and methods utilizing the same
AU8748101A (en) A novel polypeptide, a human protein stat2 and the polynucleotide encoding the polypeptide
AU4631501A (en) A novel polypeptide, a human protein kinase tak1-27 and the polynucleotide encoding the polypeptide
AU2003230516A1 (en) Fusion polypeptide, use thereof and methods employing it
AU2002314876A1 (en) Gene and polypeptide which opposes the fas pathyway
HUP0300489A3 (en) Novel protein and gene encoding the same
EP1375656A4 (fr) Nouvelles proteines et adn codant pour elle
SI1463751T1 (sl) Albumin-fuzijski proteini
AU2002252724A1 (en) The 76a11 polypeptide and uses thereof
AU9364501A (en) A novel polypeptide, a human protein plp39 and the polynucleotide encoding the polypeptide
IL204767A (en) Stable chimeric oligomeric proteins for denture and protease resistant
AU2002306943A1 (en) Reducing the immunogenicity of fusion proteins